Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05174221




Registration number
NCT05174221
Ethics application status
Date submitted
14/12/2021
Date registered
30/12/2021
Date last updated
11/12/2023

Titles & IDs
Public title
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
Scientific title
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
Secondary ID [1] 0 0
2021-005023-20
Secondary ID [2] 0 0
TAK-079-1006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney Disease 0 0
Glomerulonephritis 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Mezagitamab

Experimental: Mezagitamab - Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in LTE Retreatment Period.


Treatment: Drugs: Mezagitamab
TAK-079 subcutaneous injection.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Main Study: Percentage of Participants With one or More Treatment-emergent Adverse Events (TEAEs), Grade 3 or Higher TEAEs, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Mezagitamab Discontinuation
Timepoint [1] 0 0
Up to Week 48
Primary outcome [2] 0 0
LTE Observation Period: Percentage of Participants With one or More TEAEs, Grade 3 or Higher TEAEs and SAEs
Timepoint [2] 0 0
Up to Week 96
Primary outcome [3] 0 0
LTE Retreatment Period: Percentage of Participants With one or More TEAEs, SAEs, Grade 3 or Higher TEAEs and AEs leading to Mezagitamab Discontinuation
Timepoint [3] 0 0
Retreatment Week 0 to 48
Secondary outcome [1] 0 0
Main Study: Ctrough: Observed Serum Trough Concentrations of Mezagitamab
Timepoint [1] 0 0
Week 0 Pre-dose and at multiple time points (up to Week 48)
Secondary outcome [2] 0 0
Main Study: Serum IgA Levels
Timepoint [2] 0 0
Week 0 Pre-dose and at multiple time points (up to Week 48)
Secondary outcome [3] 0 0
Main Study: Percent Change From Baseline in Proteinuria Based on Urine Protein to Creatinine Ratio (UPCR)
Timepoint [3] 0 0
Week 36
Secondary outcome [4] 0 0
Main Study: Percentage of Participants Based on Antidrug Antibody (ADA) Levels in Serum
Timepoint [4] 0 0
Up to Week 48
Secondary outcome [5] 0 0
LTE Observation Period: Serum IgA Levels
Timepoint [5] 0 0
Week 56 Pre-dose and at multiple time points (up to Week 96)
Secondary outcome [6] 0 0
LTE Observation Period: Percent Change From Baseline in Proteinuria Based on UPCR
Timepoint [6] 0 0
Up to Week 96
Secondary outcome [7] 0 0
LTE Observation Period: Percentage of Participants Based on ADA Levels in Serum
Timepoint [7] 0 0
Up to Week 96
Secondary outcome [8] 0 0
LTE Retreatment Period: Percentage of Participants Based on ADA Levels in Serum
Timepoint [8] 0 0
Up to Retreatment Week 48

Eligibility
Key inclusion criteria
1. Renal biopsy report supporting diagnosis of primary IgAN or IgA vasculitis-associated
nephritis within 10 years prior to the screening visit.

2. UPCR greater than or equal to (>=) 1 milligram per milligram (mg/mg) or urine protein
excretion (UPE) >=1 gram per day (g/day) by 24-hour urine collection during the
screening period.

3. Estimated glomerular filtration rate (eGFR) >=45 milliliter per minute per 1.73 square
meter (mL/min/1.73m^2) at screening.

4. Receiving stable background therapy for IgAN (angiotensin-converting enzyme inhibitor
[ACE-I] or angiotensin receptor blocker [ARB]) for 12 weeks prior to screening. The
ACE-I and ARB dose should represent the maximum tolerated or maximum labeled dose, as
determined by the investigator, for a minimum of 3 months and remain stable during the
entire duration of the study.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Kidney biopsy confirming significant renal disease other than IgAN.

2. Secondary IgAN (such as with significant liver disease, inflammatory bowel disease,
and seronegative spondyloarthropathies).

3. Evidence of rapidly progressive glomerulonephritis (loss of >=50 percent (%) of eGFR
within 3 months prior to the screening visit).

4. Diagnosis of nephrotic syndrome defined as 24-hour proteinuria greater than (>) 3.5
g/day, hypoalbuminemia (smaller than [<] 30 g/dL) with or without peripheral edema at
the screening visit.

5. Diagnosis of acute active extrarenal IgA vasculitis (Henoch-Schönlein purpura)
manifested by the involvement of other organs (palpable purpura, abdominal pain, and
arthritis) at the screening visit and within 1 year prior to the screening visit.

6. Previous treatment with immunosuppressive agents such as cyclophosphamide,
mycophenolate mofetil (MMF), cyclosporine, azathioprine, calcineurin inhibitors within
6 months prior to the screening visit or expected use of any of these agents for the
duration of the study.

7. Use of systemic corticosteroids within 4 months from screening visit or expected use
for the duration of the study.

Use of B-cell-directed biologic therapies such as blisibimod, belimumab, rituximab,
ocrelizumab or have used other biologics (example, anti-tumor necrosis factor [TNF],
abatacept, anti-interleukin [IL]-6) within 6 months prior to the screening visit or
expected use of any of these agents for the duration of the study.

8. Participation in another investigational study within 4 weeks or 5 half-lives of study
drug, whichever is longer, before the screening visit (the 4-week window is derived
from the date of the last study procedure, and/or AE related to the study procedure in
the previous study, to the screening visit of the current study) or expected use of an
investigational agent from another investigational study during the time of this
study.

9. Administration of any vaccine within 28 days before the screening visit or of any live
or live-attenuated vaccination planned for the duration of the study.

10. An opportunistic infection smaller than or equal to (<=) 12 weeks before screening
visit or currently receiving treatment for a chronic opportunistic infection, such as
tuberculosis (TB), pneumocystis pneumonia, cytomegalovirus, herpes simplex virus,
herpes zoster, or atypical mycobacteria. A mild, localized herpes simplex infection
within 12 weeks of study dosing is allowed, as long as the lesion has resolved prior
to Day 1.

11. A positive T-cell interferon-gamma release assay (TIGRA) (result through
QuantiFERON-TB Gold test or T-Spot/Elispot) at the screening visit.

12. A positive test result for hepatitis B surface antigen, or hepatitis B core antibody,
or hepatitis C antibody, or HIV antibody/antigen at screening. However, an individual
who has a known history of chronic hepatitis C and has been treated and fully cured of
the disease, confirmed with a negative hepatitis C virus RNA polymerase chain reaction
(PCR) test at screening, is not excluded on the basis of the positive hepatitis C
antibody alone.

13. Inadequate organ and bone marrow function at screening visit.

14. Presence of uncontrolled or New York Heart Association (NYHA 1994) Class 3 or 4
congestive heart failure at the screening visit.

15. Uncontrolled diabetes manifested by glycosylated hemoglobin (HbA1c) >8% at the
screening visit.

16. Current malignancy or history of malignancy during the previous 5 years, except
adequately treated basal cell or squamous cell carcinomas of the skin or carcinoma in
situ/cervical intraepithelial neoplasia of the uterine cervix.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
23/03/2026
Actual
Sample size
Target
16
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Core Research Group - Milton
Recruitment hospital [2] 0 0
Monash Health, Monash Medical Centre - Clayton
Recruitment hospital [3] 0 0
Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
4064 - Milton
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Idaho
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
China
State/province [4] 0 0
Beijing
Country [5] 0 0
China
State/province [5] 0 0
Guangdong
Country [6] 0 0
China
State/province [6] 0 0
Shaanxi
Country [7] 0 0
Hungary
State/province [7] 0 0
Csongrad
Country [8] 0 0
Hungary
State/province [8] 0 0
Budapest
Country [9] 0 0
Italy
State/province [9] 0 0
Lombardia
Country [10] 0 0
Japan
State/province [10] 0 0
Aiti
Country [11] 0 0
Japan
State/province [11] 0 0
Hirosima
Country [12] 0 0
Japan
State/province [12] 0 0
Hokkaido
Country [13] 0 0
Korea, Republic of
State/province [13] 0 0
Seoul Teugbyeolsi
Country [14] 0 0
Korea, Republic of
State/province [14] 0 0
Suwon-si
Country [15] 0 0
Singapore
State/province [15] 0 0
Singapore
Country [16] 0 0
Spain
State/province [16] 0 0
Cantabria
Country [17] 0 0
Spain
State/province [17] 0 0
Barcelona
Country [18] 0 0
Taiwan
State/province [18] 0 0
New Taipei City
Country [19] 0 0
Taiwan
State/province [19] 0 0
Taipei
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Leicestershire
Country [21] 0 0
United Kingdom
State/province [21] 0 0
Hull

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will have two parts. The main aims are to:

- check the side effects from mezagitamab.

- check for long-term side effects from mezagitamab.

Before starting the study, participants will be asked to provide a 24-hour urine sample. A
few weeks later, if enrolled they will begin receiving a subcutaneous injection (under the
skin) of mezagitamab once a week for 8 weeks then once every 2 weeks for 16 weeks. When
treatment has ended, there will be a 24-week follow-up period.

Participants who receive benefit from the treatment may continue in the second part of the
study where they will be monitored for up to 96 weeks and possibly retreated for another 24
weeks.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05174221
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries